Mirimanoff René-Olivier
Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) Rue du Bugnon 46, CH-1011 LAUSANNE, Switzerland.
Curr Oncol Rep. 2006 Jan;8(1):50-3. doi: 10.1007/s11912-006-0009-5.
The dismal prognosis of glioblastoma had remained unchanged for the past 30 years until the association of temozolomide and radiotherapy in the breakthrough European Organization for Cancer/National Cancer Institute of Canada (EORTC/NCIC) trial brought new hope for patients. This trial will serve as a platform for new and exciting clinical and translational research areas. We review here the role of standard radiotherapy and chemotherapy in glioblastoma and the potential causes of their failure, and we focus on some of the aspects that led to the successful EORTC/NCIC trial and some of the related studies.
在过去30年里，胶质母细胞瘤的预后一直很糟糕，没有任何变化，直到替莫唑胺与放疗联合应用于具有突破性意义的欧洲癌症研究与治疗组织/加拿大国家癌症研究所（EORTC/NCIC）试验，才给患者带来了新的希望。该试验将成为新的、令人兴奋的临床和转化研究领域的一个平台。我们在此回顾标准放疗和化疗在胶质母细胞瘤中的作用及其失败的潜在原因，并重点关注促成EORTC/NCIC试验成功的一些方面以及一些相关研究。
